---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-010140"
form_type: "8-K"
ticker: "RVPH"
cik: "0001742927"
company_name: "REVIVA PHARMACEUTICALS HOLDINGS, INC."
filed_at: "2026-03-30T23:59:59+00:00"
generated_at: "2026-05-15T08:24:35.629611+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Reviva reports FY2025 net loss of $19.9M; FDA requires second Phase 3 trial for schizophrenia drug

## Summary
- Net loss of $19.9M ($5.48 per share) vs $29.9M ($17.73) in FY2024.
- Cash and equivalents $14.4M at Dec 31, 2025; ~$23M after March 2026 offering, funding into Q1-2027.
- FDA recommended a second Phase 3 trial (RECOVER-2) for brilaroxazine in schizophrenia; initiation planned mid-2026.
- Positive 1-year open-label extension data: sustained efficacy, benign weight gain (~1.5 kg), no motor side effects.
- Completed public offerings totaling $29M in 2025 and early 2026; intends to fund RECOVER-2 trial.

## SEC filing metadata
- accession: 0001437749-26-010140
- form_type: 8-K
- ticker: RVPH
- cik: 0001742927
- company_name: REVIVA PHARMACEUTICALS HOLDINGS, INC.
- filed_at: 2026-03-30T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1742927/000143774926010140/0001437749-26-010140-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1742927/000143774926010140/rvph20260313_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-010140
- JSON: https://secwatch.observer/filing/0001437749-26-010140.json
- Plain text: https://secwatch.observer/filing/0001437749-26-010140.txt

## Key facts
- Earnings Releases
  REVIVA PHARMACEUTICALS HOLDINGS, INC. reported financial results for the full year ended December 31, 2025.
  - Period: the full year ended December 31, 2025
  - Result: reported results
  source text: Reviva Reports Full Year 2025 Financial Results and Recent Business Highlights
  evidence_url: https://www.sec.gov/Archives/edgar/data/1742927/000143774926010140/0001437749-26-010140-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.